KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Amortization of Deferred Charges (2016 - 2023)

Pacific Biosciences Of California (PACB) has 11 years of Amortization of Deferred Charges data on record, last reported at $168000.0 in Q2 2023.

  • For Q2 2023, Amortization of Deferred Charges rose 1.2% year-over-year to $168000.0; the TTM value through Jun 2023 reached $645000.0, up 2.06%, while the annual FY2022 figure was $640000.0, 18.74% up from the prior year.
  • Amortization of Deferred Charges reached $168000.0 in Q2 2023 per PACB's latest filing, up from $156000.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $1.4 million in Q3 2019 and bottomed at -$742000.0 in Q4 2019.
  • Average Amortization of Deferred Charges over 5 years is $177750.0, with a median of $159000.0 recorded in 2021.
  • The widest YoY moves for Amortization of Deferred Charges: up 424.71% in 2019, down 369.82% in 2019.
  • A 5-year view of Amortization of Deferred Charges shows it stood at -$742000.0 in 2019, then grew by 21.83% to -$580000.0 in 2020, then surged by 127.24% to $158000.0 in 2021, then rose by 1.27% to $160000.0 in 2022, then increased by 5.0% to $168000.0 in 2023.
  • Per Business Quant database, its latest 3 readings for Amortization of Deferred Charges were $168000.0 in Q2 2023, $156000.0 in Q1 2023, and $160000.0 in Q4 2022.